Medicine and Health Sciences Commons^™

Results Of A Phase I Trial Of Induction Cisplatin, Docetaxel, 5-Fu And Erlotinib Followed By Cisplatin, Bevacizumab And Erlotinib With Radiotherapy For Advanced Head And Neck Cancer, P. H. Ahn, M. Machtay, P. R. Anné, E. Wuthrick, W. M. Keane, D. Cognetti, A. P. Dicker, R. S. Axelrod

Bodine Journal

Background: A phase I trial of induction cisplatin, docetaxel, 5-FU and erlotinib (TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) with radiotherapy (XRT) for advanced head and neck cancer (HNC) was conducted.

American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Effect Of Cediranib, Temozolamide And Radiotherapy In U87 Gbm Wtegfr And Egfrviii-Expressing Xenografts, P. Wachsberger, R. Y, Lawrence, Y. Liu, B. Andersen, A. P. Dicker

Bodine Journal

Introduction: Glioblastomas (GBM) frequently overexpress the epidermal growth factor receptor (wtEGFR) or its mutant, EGFRvIII contributing to radioresistance. New treatment strategies for GBM include blockade of EGFR signaling and angiogenesis. Cediranib (CD) is a highly potent VEGFR-2 RTKI that inhibits all three VEGF receptors. This study investigated the radiosensitizing potential of CD in combination with temozolamide (TMZ) in U87 GBM xenografts expressing wtEGFR or EGFRvIII.

Radiation Research Society (RRS) 8th Annual Meeting September 25-29, Maui, HI

Oncolog Volume 55, Number 10, October 2010, Sunni Hoseman, Stephanie Deming

OncoLog MD Anderson's Report to Physicians (All issues)

• Protecting the Patient during Radiation Theraphy: Staff expertise and equipment accuracy are essential to safe and effective treatment
• Compass Fall 2010: Stage II Colon Cancer: Adjuvant Therapy? After Surgery, some patients benefit from chemotherapy
• HOUSE CALL: Managing Cancer-Related Pain
• INBRIEF: Researchers identify Enzyme Involved in Chemotherapy Resistance

Oncolog Volume 55, Number 04-05, April-May 2010, John Lebas, Sunni Hoseman

OncoLog MD Anderson's Report to Physicians (All issues)

• IMAGING NERVES: Tetnus Toxin Offers Promise for Neurography
• INBRIEF: Fight-or-Flight Hormones Linked to Metastasis/Drug Combination Shows Promise for Colon Cancer Chemoprevention
• Compass Spring 2010: Early Uterine Papillary Serous Carcinoma: Treatment Options Tailored to Patient and Disease Characteristcs
• House Call: Addressing the Cosmetic Effects of Breast Cancer

Oncolog Volume 55, Number 03, March 2010, Bryan Tutt, Joe Munch

OncoLog MD Anderson's Report to Physicians (All issues)

• Benign Tumors That Cause Big Problems:Fortunately, parathyroid tumors can be removed with minimally invasive surgery.
• Preventing Bone Loss nad Fractures in Cancer Patients
• INBRIEF: Leukemia Cells Observed Burning Fat to Evade Death/Assesment Tool Takes Aim at Graft-versus-Host Disease
• House call: Immunotherapy:Boosting the Body's Fight Against Cancer

Oncolog Volume 55, Number 01, January 2010, Bryan Tutt, Bita Esmaeli

OncoLog MD Anderson's Report to Physicians (All issues)

"

• Ocular Cancer: Tumors of the eye threaten sight and often indicate presence of extensive disease
• Eye Care for Cancer Patients
• Doctors Team Up to Battle Retinoblastoma
• Compass Winter 2010: Ductal Carcinoma In Situ: Choosing Treatment for a Common Group of Early, Confined Breast Cancers
• Toward Tomorrow
• House Call: Three Targets for New Year's Resolutions

"